{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T09:55:29Z","timestamp":1776851729911,"version":"3.51.2"},"reference-count":40,"publisher":"The Endocrine Society","issue":"6","license":[{"start":{"date-parts":[[2022,2,3]],"date-time":"2022-02-03T00:00:00Z","timestamp":1643846400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/501100016071","name":"Goldschmidt-Jacobson Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100016071","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Swiss National Foundation"},{"DOI":"10.13039\/100016015","name":"University Hospital Basel","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016015","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008485","name":"Swiss Academy of Medical Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008485","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005688","name":"G.& J. Bangerter-Rhyner Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005688","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,5,17]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Context<\/jats:title>\n                  <jats:p>Glucagon-like-peptide-1 receptor agonists (GLP-1 RAs) exert cardiovascular benefits by reducing plasma glucose, body weight, and blood pressure. The blood pressure\u2013lowering effect may be mediated by angiotensin II (ANG II) suppression and consecutive natriuresis. However, the role of ANG II and other vasoactive hormones on GLP-1 RA treatment has not been clearly defined.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>This work aimed to investigate the effect of a 3-week treatment with the GLP-1 RA dulaglutide on vasoactive hormones, that is, renin, ANG II, aldosterone, mid-regional proatrial natriuretic peptide (MP-proANP), and natriuresis in euvolemic participants.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Randomized, double-blinded, placebo-controlled, crossover trials were conducted at University Hospital Basel, Switzerland. A total of 54 euvolemic participants, including 20 healthy individuals and 34 patients with primary polydipsia, received a subcutaneous injection of dulaglutide (Trulicity) 1.5 mg and placebo (0.9% sodium chloride) once weekly over a 3-week treatment phase.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>After a 3-week treatment phase, dulaglutide showed no effect on plasma renin, plasma ANG II, or plasma aldosterone levels in comparison to placebo. Natriuresis remained unchanged or decreased on dulaglutide depending on the measured parameter. Dulaglutide significantly decreased plasma MR-proANP levels (treatment effect: 10.60 pmol\/L; 95% CI, \u201314.70 to \u20137.90; P\u2005&amp;lt;\u2005.001) and systolic blood pressure (median: 3 mm Hg; 95% CI, \u20135 to 0; P\u2005=\u2005.036), whereas heart rate increased (median: 5 bpm; 95% CI, 3-11; P\u2005&amp;lt;\u2005.001).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>In euvolemic participants, a 3-week treatment of dulaglutide reduced systolic blood pressure independently of plasma renin, ANG II, or aldosterone levels and urinary sodium excretion. The reduction in MR-proANP might be secondary to reduced arterial pulse pressure.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1210\/clinem\/dgac063","type":"journal-article","created":{"date-parts":[[2022,2,8]],"date-time":"2022-02-08T21:54:33Z","timestamp":1644357273000},"page":"e2581-e2589","source":"Crossref","is-referenced-by-count":4,"title":["Effect of a 3-Week Treatment with GLP-1 Receptor Agonists on Vasoactive Hormones in Euvolemic Participants"],"prefix":"10.1210","volume":"107","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9181-3765","authenticated-orcid":false,"given":"Tanja","family":"Vukajlovic","sequence":"first","affiliation":[{"name":"Departments of Endocrinology, Diabetology and Metabolism, University Hospital Basel, 4031 Basel, Switzerland"},{"name":"Department of Clinical Research, University of Basel, 4056 Basel, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clara O","family":"Sailer","sequence":"additional","affiliation":[{"name":"Departments of Endocrinology, Diabetology and Metabolism, University Hospital Basel, 4031 Basel, Switzerland"},{"name":"Department of Clinical Research, University of Basel, 4056 Basel, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ali","family":"Asmar","sequence":"additional","affiliation":[{"name":"Department of Clinical Physiology, Nuclear Medicine & PET, Rigshospitalet, Copenhagen University Hospital, 2100 Copenhagen, Denmark"},{"name":"Department of Clinical Physiology and Nuclear Medicine, Bispebjerg and Frederiksberg Hospital, University Hospital of Copenhagen, 2100 Copenhagen, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Boye L","family":"Jensen","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular and Renal Research, Institute of Molecular Medicine, University of Southern Denmark, 5230 Odense, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deborah R","family":"Vogt","sequence":"additional","affiliation":[{"name":"Clinical Trial Unit, Department of Clinical Research, University of Basel and University Hospital Basel, 4056 Basel, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6336-0965","authenticated-orcid":false,"given":"Mirjam","family":"Christ-Crain","sequence":"additional","affiliation":[{"name":"Departments of Endocrinology, Diabetology and Metabolism, University Hospital Basel, 4031 Basel, Switzerland"},{"name":"Department of Clinical Research, University of Basel, 4056 Basel, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8305-2700","authenticated-orcid":false,"given":"Bettina","family":"Winzeler","sequence":"additional","affiliation":[{"name":"Departments of Endocrinology, Diabetology and Metabolism, University Hospital Basel, 4031 Basel, Switzerland"},{"name":"Department of Clinical Research, University of Basel, 4056 Basel, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"80","published-online":{"date-parts":[[2022,2,3]]},"reference":[{"issue":"4","key":"2022051722333776600_CIT0001","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1152\/physrev.00034.2006","article-title":"The physiology of glucagon-like peptide 1","volume":"87","author":"Holst","year":"2007","journal-title":"Physiol Rev."},{"issue":"10","key":"2022051722333776600_CIT0002","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1038\/nrneph.2017.123","article-title":"GLP-1 and the kidney: from physiology to pharmacology and outcomes in diabetes","volume":"13","author":"Muskiet","year":"2017","journal-title":"Nat Rev Nephrol."},{"issue":"10","key":"2022051722333776600_CIT0003","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/S2213-8587(21)00203-5","article-title":"Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials","volume":"9","author":"Sattar","year":"2021","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"8","key":"2022051722333776600_CIT0004","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1111\/dom.12085","article-title":"Blood pressure-lowering effects of GLP-1 receptor agonists exenatide and liraglutide: a meta-analysis of clinical trials","volume":"15","author":"Wang","year":"2013","journal-title":"Diabetes Obes Metab."},{"issue":"4","key":"2022051722333776600_CIT0005","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med."},{"issue":"19","key":"2022051722333776600_CIT0006","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med."},{"issue":"7","key":"2022051722333776600_CIT0007","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.2337\/dc19-2251","article-title":"Cardiovascular risk reduction with liraglutide: an exploratory mediation analysis of the LEADER trial","volume":"43","author":"Buse","year":"2020","journal-title":"Diabetes Care."},{"issue":"1","key":"2022051722333776600_CIT0008","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s12902-018-0332-5","article-title":"Effect of liraglutide on blood pressure: a meta-analysis of liraglutide randomized controlled trials","volume":"19","author":"Zhao","year":"2019","journal-title":"BMC Endocr Disord."},{"issue":"5","key":"2022051722333776600_CIT0009","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1038\/nm.3128","article-title":"GLP-1 receptor activation and Epac2 link atrial natriuretic peptide secretion to control of blood pressure","volume":"19","author":"Kim","year":"2013","journal-title":"Nat Med."},{"key":"2022051722333776600_CIT0010","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2014.00023","article-title":"Tissue renin-angiotensin systems: a unifying hypothesis of metabolic disease","volume":"5","author":"Skov","year":"2014","journal-title":"Front Endocrinol (Lausanne)."},{"issue":"7","key":"2022051722333776600_CIT0011","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1210\/jc.2019-00004","article-title":"Extracellular fluid volume expansion uncovers a natriuretic action of GLP-1: a functional GLP-1-renal axis in man","volume":"104","author":"Asmar","year":"2019","journal-title":"J Clin Endocrinol Metab."},{"issue":"6","key":"2022051722333776600_CIT0012","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1111\/dom.12651","article-title":"Short-term effects of liraglutide on kidney function and vasoactive hormones in type 2 diabetes: a randomized clinical trial","volume":"18","author":"Skov","year":"2016","journal-title":"Diabetes Obes Metab."},{"issue":"15","key":"2022051722333776600_CIT0013","doi-asserted-by":"crossref","first-page":"e14519","DOI":"10.14814\/phy2.14519","article-title":"Increased oral sodium chloride intake in humans amplifies selectively postprandial GLP-1 but not GIP, CCK, and gastrin in plasma","volume":"8","author":"Asmar","year":"2020","journal-title":"Physiol Rep."},{"issue":"4","key":"2022051722333776600_CIT0014","doi-asserted-by":"crossref","first-page":"E664","DOI":"10.1210\/jc.2012-3855","article-title":"Glucagon-like peptide-1 (GLP-1): effect on kidney hemodynamics and renin-angiotensin-aldosterone system in healthy men","volume":"98","author":"Skov","year":"2013","journal-title":"J Clin Endocrinol Metab."},{"issue":"2","key":"2022051722333776600_CIT0015","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1111\/dom.12808","article-title":"The effect of liraglutide on renal function: a randomized clinical trial","volume":"19","author":"von Scholten","year":"2017","journal-title":"Diabetes Obes Metab."},{"issue":"2","key":"2022051722333776600_CIT0016","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1007\/s12020-020-02394-2","article-title":"Effects of glucagon-like peptide-1 receptor agonists on fluid intake in healthy volunteers","volume":"70","author":"Winzeler","year":"2020","journal-title":"Endocrine."},{"issue":"20","key":"2022051722333776600_CIT0017","doi-asserted-by":"crossref","first-page":"e151800","DOI":"10.1172\/JCI151800","article-title":"A randomized controlled trial of GLP-1 receptor agonist dulaglutide in primary polydipsia","volume":"131","author":"Winzeler","year":"2021","journal-title":"J Clin Invest."},{"issue":"1","key":"2022051722333776600_CIT0018","doi-asserted-by":"crossref","first-page":"R1","DOI":"10.1152\/ajpregu.2000.278.1.R1","article-title":"Determinants of the natriuresis after acute, slow sodium loading in conscious dogs","volume":"278","author":"Bie","year":"2000","journal-title":"Am J Physiol Regul Integr Comp Physiol."},{"key":"2022051722333776600_CIT0019","volume-title":"R: A Language and Environment for Statistical Computing","author":"R Development Core Team","year":"2021"},{"key":"2022051722333776600_CIT0020","article-title":"Supplementary data for \u201cEffect of a three-week treatment with glucagon-like peptide 1 receptor agonists on vasoactive hormones in euvolemic participants.\u201d","author":"Vukajlovic","year":"2022"},{"issue":"1","key":"2022051722333776600_CIT0021","doi-asserted-by":"crossref","first-page":"132","DOI":"10.2337\/dc14-1958","article-title":"Liraglutide promotes natriuresis but does not increase circulating levels of atrial natriuretic peptide in hypertensive subjects with type 2 diabetes","volume":"38","author":"Lovshin","year":"2015","journal-title":"Diabetes Care."},{"issue":"7","key":"2022051722333776600_CIT0022","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1111\/j.1464-5491.1989.tb01238.x","article-title":"Increased proximal tubular sodium reabsorption in hypertensive patients with type 2 diabetes","volume":"6","author":"Mbanya","year":"1989","journal-title":"Diabet Med."},{"issue":"3","key":"2022051722333776600_CIT0023","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1210\/jc.2015-3885","article-title":"Altered plasma levels of glucagon, GLP-1 and glicentin during OGTT in adolescents with obesity and type 2 diabetes","volume":"101","author":"Manell","year":"2016","journal-title":"J Clin Endocrinol Metab."},{"issue":"8","key":"2022051722333776600_CIT0024","doi-asserted-by":"crossref","first-page":"E641","DOI":"10.1152\/ajpendo.00429.2014","article-title":"Renal extraction and acute effects of glucagon-like peptide-1 on central and renal hemodynamics in healthy men","volume":"308","author":"Asmar","year":"2015","journal-title":"Am J Physiol Endocrinol Metab."},{"issue":"2-3","key":"2022051722333776600_CIT0025","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1159\/000094334","article-title":"Glucagon-like peptide-1 is involved in sodium and water homeostasis in humans","volume":"73","author":"Gutzwiller","year":"2006","journal-title":"Digestion."},{"issue":"6","key":"2022051722333776600_CIT0026","doi-asserted-by":"crossref","first-page":"3055","DOI":"10.1210\/jc.2003-031403","article-title":"Glucagon-like peptide 1 induces natriuresis in healthy subjects and in insulin-resistant obese men","volume":"89","author":"Gutzwiller","year":"2004","journal-title":"J Clin Endocrinol Metab."},{"issue":"1","key":"2022051722333776600_CIT0027","doi-asserted-by":"crossref","first-page":"e11","DOI":"10.1210\/clinem\/dgaa643","article-title":"The renal extraction and the natriuretic action of GLP-1 in humans depend on interaction with the GLP-1 receptor","volume":"106","author":"Asmar","year":"2021","journal-title":"J Clin Endocrinol Metab."},{"issue":"3","key":"2022051722333776600_CIT0028","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1111\/dme.12594","article-title":"Time course and mechanisms of the anti-hypertensive and renal effects of liraglutide treatment","volume":"32","author":"von Scholten","year":"2015","journal-title":"Diabet Med."},{"issue":"6","key":"2022051722333776600_CIT0029","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1111\/dom.12884","article-title":"Effects of liraglutide on cardiovascular risk biomarkers in patients with type 2 diabetes and albuminuria: a sub-analysis of a randomized, placebo-controlled, double-blind, crossover trial","volume":"19","author":"von Scholten","year":"2017","journal-title":"Diabetes Obes Metab."},{"issue":"1","key":"2022051722333776600_CIT0030","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1530\/EC-17-0327","article-title":"Effect of liraglutide on atrial natriuretic peptide, adrenomedullin, and copeptin in PCOS","volume":"7","author":"Fr\u00f8ssing","year":"2018","journal-title":"Endocr Connect."},{"issue":"8","key":"2022051722333776600_CIT0031","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1373\/clinchem.2012.202416","article-title":"Plasma proANP decreases after meal intake","volume":"59","author":"Goetze","year":"2013","journal-title":"Clin Chem."},{"issue":"2","key":"2022051722333776600_CIT0032","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1111\/j.1475-097X.1988.tb00204.x","article-title":"Atrial natriuretic peptide during acute treatment of congestive heart failure","volume":"8","author":"Berglund","year":"1988","journal-title":"Clin Physiol."},{"issue":"1-3","key":"2022051722333776600_CIT0033","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.regpep.2004.08.024","article-title":"Glucagon-like peptide-1 relaxes rat conduit arteries via an endothelium-independent mechanism","volume":"125","author":"Nystr\u00f6m","year":"2005","journal-title":"Regul Pept."},{"key":"2022051722333776600_CIT0034","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/1475-2840-13-36","article-title":"Changes in liraglutide-induced body composition are related to modifications in plasma cardiac natriuretic peptides levels in obese type 2 diabetic patients","volume":"13","author":"Li","year":"2014","journal-title":"Cardiovasc Diabetol."},{"issue":"4","key":"2022051722333776600_CIT0035","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1210\/en.2013-1934","article-title":"GLP-1 receptor localization in monkey and human tissue: novel distribution revealed with extensively validated monoclonal antibody","volume":"155","author":"Pyke","year":"2014","journal-title":"Endocrinology."},{"issue":"5","key":"2022051722333776600_CIT0036","first-page":"G984","article-title":"Glucagon-like peptide-1 inhibits gastropancreatic function by inhibiting central parasympathetic outflow","volume":"275","author":"Wettergren","year":"1998","journal-title":"Am J Physiol."},{"issue":"9","key":"2022051722333776600_CIT0037","doi-asserted-by":"crossref","first-page":"E744","DOI":"10.1152\/ajpendo.00518.2015","article-title":"Glucagon-like peptide-1 does not have acute effects on central or renal hemodynamics in patients with type 2 diabetes without nephropathy","volume":"310","author":"Asmar","year":"2016","journal-title":"Am J Physiol Endocrinol Metab."},{"issue":"3","key":"2022051722333776600_CIT0038","doi-asserted-by":"crossref","first-page":"e13073","DOI":"10.14814\/phy2.13073","article-title":"Glucagon-like peptide-1 elicits vasodilation in adipose tissue and skeletal muscle in healthy men","volume":"5","author":"Asmar","year":"2017","journal-title":"Physiol Rep."},{"issue":"4","key":"2022051722333776600_CIT0039","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1111\/dom.12849","article-title":"Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: a systematic review and mixed-treatment comparison analysis","volume":"19","author":"Htike","year":"2017","journal-title":"Diabetes Obes Metab."},{"issue":"11","key":"2022051722333776600_CIT0040","doi-asserted-by":"crossref","first-page":"2513","DOI":"10.1111\/dom.14497","article-title":"An indirect treatment comparison of the efficacy of semaglutide 1.0 mg versus dulaglutide 3.0 and 4.5 mg","volume":"23","author":"Pratley","year":"2021","journal-title":"Diabetes Obes Metab."}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/clinem\/dgac063\/42558558\/dgac063.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/107\/6\/e2581\/43739001\/dgac063.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/107\/6\/e2581\/43739001\/dgac063.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,17]],"date-time":"2022-05-17T22:35:41Z","timestamp":1652826941000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/107\/6\/e2581\/6521260"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,3]]},"references-count":40,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2022,2,3]]},"published-print":{"date-parts":[[2022,5,17]]}},"URL":"https:\/\/doi.org\/10.1210\/clinem\/dgac063","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,6,1]]},"published":{"date-parts":[[2022,2,3]]}}}